{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:17Z","timestamp":1791920177274,"version":"4.3.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T00:00:00Z","timestamp":1372118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the evidence for lorcaserin and phentermine\/topiramate in the treatment of obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>Literature was accessed through PubMed (June 1975-March 2013) using the search terms lorcaserin, phentermine, topiramate, or phentermine\/topiramate. Additionally, reference citations from publications identified were reviewed. Additional information was obtained from the Food and Drug Administration (FDA)\u2013approved prescribing information and FDA briefing documents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION<\/jats:title>\n                    <jats:p>English-language articles focusing on Phase 3 clinical trials for obesity were critiqued. Data from preclinical and Phase 1 and\/or 2 trials are reported when appropriate. Six prospective Phase 3 trials were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS<\/jats:title>\n                    <jats:p>\n                      Obesity has reached epidemic proportions, affecting more than one third of adults in the US. Two medication products, lorcaserin and phentermine\/topiramate, have recently received FDA approval as adjuncts to a reduced-calorie diet and increased physical activity among individuals with a body mass index greater than or equal to 30 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      or greater than or equal to 27 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      with an obesity-related comorbidity, such as hypertension, dyslipidemia, or diabetes. Lorcaserin is a selective serotonin 5-HT\n                      <jats:sub>2C<\/jats:sub>\n                      agonist that regulates food intake, while the combination of phentermine\/topiramate causes appetite suppression and enhanced satiety. Three Phase 3 randomized, placebo-controlled trials reported approximately 75% and 45% of patients achieved greater than or equal to 5% weight loss with phentermine\/topiramate and lorcaserin, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>With lifestyle modification, phentermine\/topiramate appears most effective in terms of weight loss. Lorcaserin demonstrates moderate efficacy. Long-term cardiovascular outcomes studies are needed to confirm the safety and benefit of these new obesity agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1r779","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T23:27:39Z","timestamp":1372202859000},"page":"1007-1016","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":58,"title":["New Obesity Agents: Lorcaserin and Phentermine\/Topiramate"],"prefix":"10.1177","volume":"47","author":[{"given":"Joshua W","family":"Fleming","sequence":"first","affiliation":[{"name":"Joshua W Fleming PharmD, Clinical Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, University of Mississippi, Jackson, MS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie S","family":"McClendon","sequence":"additional","affiliation":[{"name":"Katie S McClendon PharmD, Clinical Assistant Professor, Department of Pharmacy Practice, School of Pharmacy, University of Mississippi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Riche","sequence":"additional","affiliation":[{"name":"Daniel M Riche PharmD BCPS CDE, Assistant Professor, Departments of Pharmacy Practice and Medicine, School of Pharmacy, School of Medicine, University of Mississippi"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"key":"bibr1-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1159\/000336672"},{"key":"bibr2-aph.1R779","first-page":"1","volume":"50","author":"Ogden CL","year":"2010","journal-title":"NCHS Data Brief"},{"key":"bibr3-aph.1R779","first-page":"1","volume":"82","author":"Ogden CL","year":"2012","journal-title":"NCHS Data Brief"},{"key":"bibr4-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.28.5.w822"},{"key":"bibr5-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"bibr6-aph.1R779","unstructured":"6. FDA announces withdrawal fenfluramine and dexfenfluramine (Fen-Phen). www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm179871.htm (accessed 2012 Aug 16)."},{"key":"bibr7-aph.1R779","unstructured":"7. FDA drug safety communication: FDA recommends against the continued use of Meridia (sibutramine). www.fda.gov\/Drugs\/DrugSafety\/ucm228746.htm (accessed 2013 Feb 4)."},{"key":"bibr8-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903321485"},{"key":"bibr9-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.01.001"},{"key":"bibr10-aph.1R779","volume-title":"Product information. Xenical (orlistat)","year":"2013"},{"key":"bibr11-aph.1R779","volume-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report","author":"NIH publication no. 98\u20134083","year":"1998"},{"key":"bibr12-aph.1R779","volume-title":"Product information. Belviq (loraserin hydrochloride)","year":"2012"},{"key":"bibr13-aph.1R779","volume-title":"Product information. Qsymia (phentermine\/topiramate)","year":"2012"},{"key":"bibr14-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"},{"key":"bibr15-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"bibr16-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.66"},{"key":"bibr17-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"bibr18-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.04.004"},{"key":"bibr19-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)01064-9"},{"key":"bibr20-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-003-0832-2"},{"key":"bibr21-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.20"},{"key":"bibr22-aph.1R779","unstructured":"22. Arena Pharmaceuticals and Eisai announce FDA approval of Belviq (lorcaserin HCl) for chronic weight management in adults who are overweight with a comorbidity or obese. http:\/\/invest.arenapharm.com\/releasedetail.cfm?releaseid=687182 (accessed 2012 Dec 13)."},{"key":"bibr23-aph.1R779","unstructured":"23. FDA briefing information: meeting of the endocrinologic and metabolic drugs advisory committee. www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/endocrinologicaandmetabolicdrugsadvisorycommittee\/ucm303198.pdf (accessed 2012 Dec 7)."},{"key":"bibr24-aph.1R779","unstructured":"24. Arena Pharmaceuticals Provides Update on Upcoming US Launch of BELVIQ (lorcaserin HCL) for Chronic Weight Management. http:\/\/invest.arenapharm.com\/releasedetail.cfm?ReleaseID=762717 (accessed 2013 Jun 13)."},{"key":"bibr25-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.303"},{"key":"bibr26-aph.1R779","volume-title":"Product information. Suprenza (phentermine hydrocholide) orally disintegrating tablet","year":"2012"},{"key":"bibr27-aph.1R779","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00012"},{"key":"bibr28-aph.1R779","volume-title":"Product information. Topamax (topiramate)","year":"2012"},{"key":"bibr29-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"bibr30-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"bibr31-aph.1R779","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"bibr32-aph.1R779","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.55602.x"},{"key":"bibr33-aph.1R779","unstructured":"33. VIVUS announces FDA approval of Qsymia REMS modification allowing access through certified retail pharmacies. http:\/\/ir.vivus.com\/releasedetail.cfm?ReleaseID=756874 (accessed 2013 Jun 17)."},{"key":"bibr34-aph.1R779","volume-title":"Red book online"},{"key":"bibr35-aph.1R779","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2204"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R779","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1R779","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1R779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:01Z","timestamp":1777374781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1R779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,25]]},"references-count":35,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1345\/aph.1R779"],"URL":"https:\/\/doi.org\/10.1345\/aph.1r779","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,25]]}}}